{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T11:07:58Z","timestamp":1786964878523,"version":"build-2736575974"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2015,9,21]],"date-time":"2015-09-21T00:00:00Z","timestamp":1442793600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1007\/s00280-015-2866-9","type":"journal-article","created":{"date-parts":[[2015,9,21]],"date-time":"2015-09-21T08:55:40Z","timestamp":1442825740000},"page":"939-948","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Etoposide pharmacokinetics impact the outcomes of lymphoma patients treated with BEAM regimen and ASCT: a multicenter study of the LYmphoma Study Association (LYSA)"],"prefix":"10.1007","volume":"76","author":[{"given":"Benoit","family":"You","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Salles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Bachy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Casasnovas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Tilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Ribrag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Sebban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"H\u00e9nin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9ome","family":"Guitton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Tod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Freyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,9,21]]},"reference":[{"key":"2866_CR1","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1023\/A:1008396525292","volume":"11","author":"A Argiris","year":"2000","unstructured":"Argiris A, Seropian S, Cooper DL (2000) High-dose BEAM chemotherapy with autologous peripheral blood progenitor-cell transplantation for unselected patients with primary refractory or relapsed Hodgkin\u2019s disease. Ann Oncol 11:665\u2013672","journal-title":"Ann Oncol"},{"key":"2866_CR2","volume-title":"NONMEM User\u2019s Guides (1989\u20132009)","author":"SL Beal","year":"2009","unstructured":"Beal SL, Sheiner LB, Boeckmann A, Bauer RJ (2009) NONMEM User\u2019s Guides (1989\u20132009). Icon, Ellicott City"},{"key":"2866_CR3","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1007\/s11095-006-9067-5","volume":"23","author":"K Brendel","year":"2006","unstructured":"Brendel K, Comets E, Laffont C, Laveille C, Mentre F (2006) Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide. Pharm Res 23:2036\u20132049","journal-title":"Pharm Res"},{"key":"2866_CR4","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","volume":"17","author":"BD Cheson","year":"1999","unstructured":"Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-Lopez A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP (1999) Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17:1244","journal-title":"J Clin Oncol"},{"key":"2866_CR5","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1097\/00007691-200212000-00005","volume":"24","author":"J Ciccolini","year":"2002","unstructured":"Ciccolini J, Monjanel-Mouterde S, Bun SS, Blanc C, Duffaud F, Favre R, Durand A (2002) Population pharmacokinetics of etoposide: application to therapeutic drug monitoring. Ther Drug Monit 24:709\u2013714","journal-title":"Ther Drug Monit"},{"key":"2866_CR6","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1200\/JCO.1994.12.7.1427","volume":"12","author":"PI Clark","year":"1994","unstructured":"Clark PI, Slevin ML, Joel SP, Osborne RJ, Talbot DI, Johnson PW, Reznek R, Masud T, Gregory W, Wrigley PF (1994) A randomized trial of two etoposide schedules in small-cell lung cancer: the influence of pharmacokinetics on efficacy and toxicity. J Clin Oncol 12:1427\u20131435","journal-title":"J Clin Oncol"},{"issue":"9","key":"2866_CR7","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1038\/leu.2014.79","volume":"28","author":"P Corradini","year":"2014","unstructured":"Corradini P, Vitolo U, Rambaldi A, Miceli R, Patriarca F, Gallamini A, Olivieri A, Benedetti F, Todeschini G, Rossi G, Salvi F, Bruno B, Baldini L, Ferreri A, Patti C, Tarella C, Pileri S, Dodero A (2014) Intensified chemo-immunotherapy with or without stem cell transplantation in newly diagnosed patients with peripheral T-cell lymphoma. Leukemia 28(9):1885\u20131891","journal-title":"Leukemia"},{"key":"2866_CR8","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1111\/j.1365-2125.2007.02975.x","volume":"64","author":"C Dartois","year":"2007","unstructured":"Dartois C, Brendel K, Comets E, Laffont CM, Laveille C, Tranchand B, Mentre F, Lemenuel-Diot A, Girard P (2007) Overview of model-building strategies in population PK\/PD analyses: 2002\u20132004 literature survey 1. Br J Clin Pharmacol 64:603\u2013612","journal-title":"Br J Clin Pharmacol"},{"key":"2866_CR9","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa022473","volume":"348","author":"V Diehl","year":"2003","unstructured":"Diehl V, Franklin J, Pfreundschuh M, Lathan B, Paulus U, Hasenclever D, Tesch H, Herrmann R, Dorken B, Muller-Hermelink HK, Duhmke E, Loeffler M (2003) Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin\u2019s disease. N Engl J Med 348:2386\u20132395","journal-title":"N Engl J Med"},{"key":"2866_CR10","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1177\/0091270003253624","volume":"43","author":"EI Ette","year":"2003","unstructured":"Ette EI, Williams PJ, Kim YH, Lane JR, Liu MJ, Capparelli EV (2003) Model appropriateness and population pharmacokinetic modeling. J Clin Pharmacol 43:610\u2013623","journal-title":"J Clin Pharmacol"},{"key":"2866_CR11","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.3324\/haematol.2010.038109","volume":"96","author":"O Fitoussi","year":"2011","unstructured":"Fitoussi O, Belhadj K, Mounier N, Parrens M, Tilly H, Salles G, Feugier P, Ferme C, Ysebaert L, Gabarre J, Herbrecht R, Janvier M, Van Den Neste E, Morschhauser F, Casasnovas O, Ghesquieres H, Anglaret B, Brechignac S, Haioun C, Gisselbrecht C (2011) Survival impact of rituximab combined with ACVBP and upfront consolidation autotransplantation in high-risk diffuse large B-cell lymphoma for GELA. Haematologica 96:1136\u20131143","journal-title":"Haematologica"},{"key":"2866_CR12","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1182\/asheducation.V2012.1.410.3798518","volume":"2012","author":"C Gisselbrecht","year":"2012","unstructured":"Gisselbrecht C (2012) Is there any role for transplantation in the rituximab era for diffuse large B-cell lymphoma? Hematol Am Soc Hematol Educ Program 2012:410\u2013416","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"Suppl 3","key":"2866_CR13","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2165\/00003495-199958003-00006","volume":"58","author":"FA Greco","year":"1999","unstructured":"Greco FA (1999) Oral etoposide in lymphoma. Drugs 58(Suppl 3):35\u201341","journal-title":"Drugs"},{"key":"2866_CR14","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1200\/JCO.1996.14.9.2590","volume":"14","author":"H Gurney","year":"1996","unstructured":"Gurney H (1996) Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. J Clin Oncol 14:2590\u20132611","journal-title":"J Clin Oncol"},{"key":"2866_CR15","doi-asserted-by":"crossref","first-page":"5074","DOI":"10.1200\/JCO.2010.30.5771","volume":"28","author":"A Josting","year":"2010","unstructured":"Josting A, Muller H, Borchmann P, Baars JW, Metzner B, Dohner H, Aurer I, Smardova L, Fischer T, Niederwieser D, Schafer-Eckart K, Schmitz N, Sureda A, Glossmann J, Diehl V, DeJong D, Hansmann ML, Raemaekers J, Engert A (2010) Dose intensity of chemotherapy in patients with relapsed Hodgkin\u2019s lymphoma. J Clin Oncol 28:5074\u20135080","journal-title":"J Clin Oncol"},{"key":"2866_CR16","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.clon.2006.10.010","volume":"19","author":"SA Kaestner","year":"2007","unstructured":"Kaestner SA, Sewell GJ (2007) Chemotherapy dosing part I: scientific basis for current practice and use of body surface area. Clin Oncol (R Coll Radiol) 19:23\u201337","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"2866_CR17","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/sj.clpt.6100241","volume":"82","author":"MO Karlsson","year":"2007","unstructured":"Karlsson MO, Savic RM (2007) Diagnosing model diagnostics. Clin Pharmacol Ther 82:17\u201320","journal-title":"Clin Pharmacol Ther"},{"key":"2866_CR18","first-page":"576","volume":"370","author":"N Milpied","year":"2014","unstructured":"Milpied N (2014) The role of myeloablation for lymphoma. N Engl J Med 370:576","journal-title":"N Engl J Med"},{"key":"2866_CR19","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.canlet.2006.11.005","volume":"252","author":"A Montecucco","year":"2007","unstructured":"Montecucco A, Biamonti G (2007) Cellular response to etoposide treatment. Cancer Lett 252:9\u201318","journal-title":"Cancer Lett"},{"issue":"Suppl 1","key":"2866_CR20","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1093\/annonc\/9.suppl_1.S15","volume":"9","author":"N Mounier","year":"1998","unstructured":"Mounier N, Gisselbrecht C (1998) Conditioning regimens before transplantation in patients with aggressive non-Hodgkin\u2019s lymphoma. Ann Oncol 9(Suppl 1):S15\u2013S21","journal-title":"Ann Oncol"},{"key":"2866_CR21","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","volume":"333","author":"T Philip","year":"1995","unstructured":"Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D, Sonneveld P, Gisselbrecht C, Cahn JY, Harousseau JL et al (1995) Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin\u2019s lymphoma. N Engl J Med 333:1540\u20131545","journal-title":"N Engl J Med"},{"key":"2866_CR22","doi-asserted-by":"crossref","unstructured":"Rancea M, Skoetz N, Monsef I, Hubel K, Engert A, Bauer K (2012) Fourteenth biannual report of the Cochrane Haematological Malignancies Group\u2014focus on autologous stem cell transplantation in hematological malignancies. J Natl Cancer Inst 104:NP","DOI":"10.1093\/jnci\/DJS278"},{"key":"2866_CR23","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/S0140-6736(02)08938-9","volume":"359","author":"N Schmitz","year":"2002","unstructured":"Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M, Boissevain F, Zschaber R, Muller P, Kirchner H, Lohri A, Decker S, Koch B, Hasenclever D, Goldstone AH, Diehl V (2002) Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin\u2019s disease: a randomised trial. Lancet 359:2065\u20132071","journal-title":"Lancet"},{"key":"2866_CR24","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1056\/NEJMoa1301077","volume":"369","author":"PJ Stiff","year":"2013","unstructured":"Stiff PJ, Unger JM, Cook JR, Constine LS, Couban S, Stewart DA, Shea TC, Porcu P, Winter JN, Kahl BS, Miller TP, Tubbs RR, Marcellus D, Friedberg JW, Barton KP, Mills GM, LeBlanc M, Rimsza LM, Forman SJ, Fisher RI (2013) Autologous transplantation as consolidation for aggressive non-Hodgkin\u2019s lymphoma. N Engl J Med 369:1681\u20131690","journal-title":"N Engl J Med"},{"key":"2866_CR25","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1007\/s002800050901","volume":"43","author":"B Tranchand","year":"1999","unstructured":"Tranchand B, Amsellem C, Chatelut E, Freyer G, Iliadis A, Ligneau B, Trillet-Lenoir V, Canal P, Lochon I, Ardiet CJ (1999) A limited-sampling strategy for estimation of etoposide pharmacokinetics in cancer patients. Cancer Chemother Pharmacol 43:316\u2013322","journal-title":"Cancer Chemother Pharmacol"},{"key":"2866_CR26","doi-asserted-by":"crossref","first-page":"345","DOI":"10.2165\/00003088-200039050-00004","volume":"39","author":"HJ Bongard van den","year":"2000","unstructured":"van den Bongard HJ, Mathot RA, Beijnen JH, Schellens JH (2000) Pharmacokinetically guided administration of chemotherapeutic agents. Clin Pharmacokinet 39:345\u2013367","journal-title":"Clin Pharmacokinet"},{"key":"2866_CR27","doi-asserted-by":"crossref","first-page":"319","DOI":"10.2165\/00003088-200746040-00005","volume":"46","author":"S Wilde","year":"2007","unstructured":"Wilde S, Jetter A, Rietbrock S, Kasel D, Engert A, Josting A, Klimm B, Hempel G, Reif S, Jaehde U, Merkel U, Busse D, Schwab M, Diehl V, Fuhr U (2007) Population pharmacokinetics of the BEACOPP polychemotherapy regimen in Hodgkin\u2019s lymphoma and its effect on myelotoxicity. Clin Pharmacokinet 46:319\u2013333","journal-title":"Clin Pharmacokinet"},{"key":"2866_CR28","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.lungcan.2008.03.008","volume":"62","author":"B You","year":"2008","unstructured":"You B, Tranchand B, Girard P, Falandry C, Ribba B, Chabaud S, Souquet PJ, Court-Fortune I, Trillet-Lenoir V, Fournel C, Tod M, Freyer G (2008) Etoposide pharmacokinetics and survival in patients with small cell lung cancer: a multicentre study. Lung Cancer 62:261\u2013272","journal-title":"Lung Cancer"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-015-2866-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-015-2866-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-015-2866-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,8]],"date-time":"2020-09-08T14:26:32Z","timestamp":1599575192000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-015-2866-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,21]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["2866"],"URL":"https:\/\/doi.org\/10.1007\/s00280-015-2866-9","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,21]]}}}